Alliance for Pandemic Preparedness

April 15, 2021

INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T Cell Activity Against Global SARS-CoV-2 Variants

Category:

Topic:

Keywords (Tags): ,

  • [Pre-print, not peer-reviewed] Neutralizing antibody activity induced by the SARS-CoV-2 vaccine candidate INO-4800 (Inovia Pharmaceuticals), a DNA-based vaccine, was reduced against variants of concern B.1.1.7 and B.1.351 compared to the wild-type strain by 2.1 and 6.9-fold, respectively. In contrast, neutralizing activity was maintained against the P.1 variant, which harbors the same E484K mutation as B.1.351 that is thought to reduce antibody activity. There was no observed difference in the post-vaccination T-cell ELISPOT responses induced by overlapping peptide pools from either the variant or the parent strain. 

Andrade et al. (Apr 14, 2021). INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T Cell Activity Against Global SARS-CoV-2 Variants. Pre-print downloaded Apr 15 from https://doi.org/10.1101/2021.04.14.439719